![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Patients of all IL28B Genotypes have High SVR Rates when Treated with VX-222 in Combination with Telaprevir/Peginterferon/Ribavirin in the ZENITH Study
|
|
|
Reported by Jules Levin
47th Annual Meeting of the European Association for the Study of the Liver (EASL), The International Liver Congress, Barcelona, Spain, 18-22 April 2012
M.S. Penney1*, C. DeSouza1, S. Seepersaud1, K. Alves1, M.J. Koziel1, R.S. Kauffman1, A.M. Di
1. Vertex Pharmaceuticals Incorporated, Cambridge, MA; 2. Saint Louis University School of Medicine, Saint Louis, MO, USA.
![EASL1.gif](../images/042412/042412-8/EASL1.gif)
YOU will note arms E & F are interferon-free, VX222 400mg bid + Telaprevir bid + Ribavirin, in 46 patients for 12 weeks, with an option of adding peg/rbv after 12 weeks of IFN-free. The results are from part of the study are not ready yet for presentation so are not in this poster but we expect it soon. Vertex has 2 nucleotides (acquired from Alios) that they are studying now in phase 1 with results expected soon, within a few months, whereupon based on these results from the phase 1 nucleotide studies new studies will quickly be designed including all of the Vertex orals which in total add up to a potential of 4 oral drugs that can be utilized in such studies (telaprevir, VX222, 2 nucleotides).
![EASL2.gif](../images/042412/042412-8/EASL2.gif)
![EASL3.gif](../images/042412/042412-8/EASL3.gif)
![EASL4.gif](../images/042412/042412-8/EASL4.gif)
![EASL5.gif](../images/042412/042412-8/EASL5.gif)
![EASL6.gif](../images/042412/042412-8/EASL6.gif)
![EASL7.gif](../images/042412/042412-8/EASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|